TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Arrowhead Pharmaceuticals ( (ARWR) ) is now available.
On November 18, 2025, Arrowhead Pharmaceuticals announced that the FDA approved REDEMPLO® (plozasiran) for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS). This approval marks Arrowhead’s first FDA-approved medicine, utilizing their proprietary TRiMTM platform, and represents a significant milestone as the company transitions into a commercial stage. REDEMPLO is the first FDA-approved siRNA treatment for FCS, offering new hope for the estimated 6,500 U.S. patients with this rare disease. The approval is based on successful Phase 3 PALISADE study results, showing significant triglyceride reduction and lower acute pancreatitis incidence compared to placebo. Arrowhead is launching a patient support program, Rely On REDEMPLO, to assist patients throughout their treatment journey.
The most recent analyst rating on (ARWR) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is driven by strong technical momentum and positive developments in its clinical pipeline and partnerships. However, significant financial challenges and valuation concerns weigh heavily on the score. The earnings call provided a cautiously optimistic outlook, but the company’s financial performance remains a critical area for improvement.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
Average Trading Volume: 2,201,882
Technical Sentiment Signal: Buy
Current Market Cap: $5.7B
For an in-depth examination of ARWR stock, go to TipRanks’ Overview page.